Newly identified chemotherapy-induced peripheral neuropathy in a childhood cancer survivorship clinic.

Chemotherapy-induced peripheral neuropathy (CIPN), a debilitating side effect of pediatric cancer therapy, can be challenging to diagnose. We estimated the prevalence of newly identified and previously diagnosed CIPN in the regional HEROS Childhood Cancer Survivorship Clinic. From 2016 to 2018, 148 survivors (45.3% female, age 17.1 [SD 7.7] years, 81.8% in ongoing routine oncology follow-up) had their initial survivorship evaluation at an average of 7.4 (SD 6.6) years from diagnosis. Fifty-six survivors (37.8%) had CIPN, of these 46 (82.1%) were newly identified. Our findings demonstrate CIPN may be missed in routine oncology care, and new methods are needed to screen for CIPN. © 2021 Wiley Periodicals LLC.

Citation

Rozalyn L Rodwin, Wilhelmenia L Ross, Jaime Rotatori, Katherine Allen, Claudia Auerbach, Lyn M Balsamo, Nina S Kadan-Lottick. Newly identified chemotherapy-induced peripheral neuropathy in a childhood cancer survivorship clinic. Pediatric blood & cancer. 2022 Mar;69(3):e29550

Mesh Tags

Substances

PMID: 34971076

search → result